Trans Genic Inc. (2342.T)
JPY 184.0
(-1.08%)
JPY 184.0
(-1.08%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.81 Billion JPY | -8.08% |
| 2022 | 10.67 Billion JPY | 2.22% |
| 2021 | 10.44 Billion JPY | 17.06% |
| 2020 | 8.91 Billion JPY | 17.8% |
| 2019 | 7.57 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 10.66 Billion JPY | 8.74% |
| 2023 Q1 | 10.37 Billion JPY | -2.78% |
| 2023 Q4 | 9.81 Billion JPY | -5.25% |
| 2023 Q3 | 10.35 Billion JPY | -1.22% |
| 2023 Q2 | 10.48 Billion JPY | 1.03% |
| 2023 FY | 9.81 Billion JPY | -8.08% |
| 2022 Q4 | 10.67 Billion JPY | -2.36% |
| 2022 FY | 10.67 Billion JPY | 2.22% |
| 2022 Q3 | 10.93 Billion JPY | 2.54% |
| 2022 Q2 | 10.66 Billion JPY | 0.0% |
| 2021 FY | 10.44 Billion JPY | 17.06% |
| 2020 FY | 8.91 Billion JPY | 17.8% |
| 2019 FY | - JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | -48.892% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -709.872% |
| GNI Group Ltd. | 62.39 Billion JPY | 84.276% |
| Linical Co., Ltd. | 18.53 Billion JPY | 47.082% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -74.135% |
| Soiken Holdings Inc. | 6.94 Billion JPY | -41.244% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -68.68% |
| AnGes, Inc. | 28.89 Billion JPY | 66.043% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -1031.244% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 93.759% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -506.148% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -93.462% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -125.546% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -303.271% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -313.378% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | -41.567% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -460.163% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -92.919% |
| PeptiDream Inc. | 67.12 Billion JPY | 85.384% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -380.79% |
| Ribomic Inc. | 3.54 Billion JPY | -176.58% |
| SanBio Company Limited | 5.04 Billion JPY | -94.381% |
| Healios K.K. | 15.15 Billion JPY | 35.262% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -697.476% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -225.298% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -565.534% |
| StemRIM | 9.08 Billion JPY | -8.051% |
| CellSource Co., Ltd. | 6.87 Billion JPY | -42.607% |
| FunPep Company Limited | 2.49 Billion JPY | -293.837% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -274.658% |
| Stella Pharma Corporation | 3.82 Billion JPY | -156.791% |
| TMS Co., Ltd. | 3.55 Billion JPY | -175.997% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -69.771% |
| Cuorips Inc. | 6.18 Billion JPY | -58.632% |
| K Pharma,Inc. | 3.31 Billion JPY | -196.056% |
| Takara Bio Inc. | 123.2 Billion JPY | 92.037% |
| ReproCELL Incorporated | 9.05 Billion JPY | -8.377% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -261.32% |
| StemCell Institute Inc. | 6.54 Billion JPY | -49.945% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | -40.382% |
| CellSeed Inc. | 2.46 Billion JPY | -297.888% |